126 related articles for article (PubMed ID: 17685465)
1. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract][Full Text] [Related]
4. BRAF
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.
Angell TE; Lechner MG; Jang JK; Correa AJ; LoPresti JS; Epstein AL
Thyroid; 2014 Sep; 24(9):1385-93. PubMed ID: 24955518
[TBL] [Abstract][Full Text] [Related]
6. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis.
Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W
J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234
[TBL] [Abstract][Full Text] [Related]
7. The BRAF
Ma CX; Ma XN; Liu JJ; Guan CH; Li YD; Zhao N; Mauricio D; Fu SB
Mol Cell Endocrinol; 2024 Feb; 581():112113. PubMed ID: 37989409
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?
Lai HF; Hang JF; Chen JY
Ann Surg Oncol; 2024 Jun; 31(6):3974-3975. PubMed ID: 38366182
[No Abstract] [Full Text] [Related]
9. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
[TBL] [Abstract][Full Text] [Related]
10. Letter to the Editor: Comment on: "BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma".
Yu ST; Lei ST
Ann Surg Oncol; 2024 Jun; 31(6):3737-3738. PubMed ID: 38512604
[No Abstract] [Full Text] [Related]
11. Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms.
Harikrishnan V; Kumari S; Ramkumar S; Sankaran R; Ramalingam S; Sairam T
Cureus; 2021 Jun; 13(6):e16048. PubMed ID: 34345541
[TBL] [Abstract][Full Text] [Related]
12.
Wieczorek-Szukala K; Kopczynski J; Kowalska A; Lewinski A
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32825554
[TBL] [Abstract][Full Text] [Related]
13. Comment on BRAFV600E mutation does not predict lymph node metastases and recurrence in Chinese papillary thyroid microcarcinoma patients.
Sekar D
Oral Oncol; 2024 May; 152():106812. PubMed ID: 38640747
[No Abstract] [Full Text] [Related]
14. Immunohistochemistry cannot replace DNA analysis for evaluation of
Szymonek M; Kowalik A; Kopczyński J; Gąsior-Perczak D; Pałyga I; Walczyk A; Gadawska-Juszczyk K; Płusa A; Mężyk R; Chrapek M; Góźdź S; Kowalska A
Oncotarget; 2017 Sep; 8(43):74897-74909. PubMed ID: 29088832
[TBL] [Abstract][Full Text] [Related]
15. The Impact of
Abdulhaleem M; Bandargal S; Pusztaszeri MP; Rajab M; Greenspoon H; Krasner JR; Da Silva SD; Forest VI; Payne RJ
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201541
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Prediction of Metastatic Lymph Nodes Posterior to the Right Recurrent Laryngeal Nerve in cN0 Papillary Thyroid Carcinoma.
Shao J; Wang X; Yu H; Ding W; Xu B; Ma D; Huang X; Yin H
Cancer Manag Res; 2024; 16():421-429. PubMed ID: 38736588
[TBL] [Abstract][Full Text] [Related]
17. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases.
Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I
Pathol Res Pract; 2024 Apr; 258():155319. PubMed ID: 38696857
[TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors.
Wu SS; Lamarre ED; Scharpf J; Prendes B; Ku JA; Silver N; Burkey B; Woody N; Campbell SR; Yilmaz E; Koyfman SA; Geiger J
Endocr Pract; 2023 Nov; 29(11):881-889. PubMed ID: 37597577
[TBL] [Abstract][Full Text] [Related]
20. TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.
Eich ML; Jeske W; Zenz U; Chiapponi C; Alidousty C; Merkelbach-Bruse S; Büttner R; Schultheis AM
Thyroid Res; 2024 Apr; 17(1):8. PubMed ID: 38616265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
